Literature DB >> 23506452

Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040.

R Waldeyer1, R Brinks, W Rathmann, G Giani, A Icks.   

Abstract

AIM: To model the future costs of Type 2 diabetes in Germany, taking into account demographic changes, disease dynamics and undiagnosed cases.
METHODS: Using a time-discrete Markov model, the prevalence of diabetes (diagnosed/undiagnosed) between 2010 and 2040 was estimated and linked with cost weights. Demographic, epidemiological and economic scenarios were modelled. Inputs to the model included the official population forecasts, prevalence, incidence and mortality rates, proportions of undiagnosed cases, health expenditure and cost ratios of an individual with (diagnosed/undiagnosed) diabetes to an individual without diabetes. The outcomes were the case numbers and associated annual direct medical excess costs of Type 2 diabetes from a societal perspective in 2010€.
RESULTS: In the base case, the case numbers of diabetes will grow from 5 million (2.8 million diagnosed) in 2010 to a maximum of 7.9 million (4.6 million diagnosed) in 2037. From 2010 to 2040, the prevalence rate amonf individuals ≥40 years old will increase from 10.5 to 16.3%. The annual costs of diabetes will increase by 79% from €11.8 billion in 2010 to €21.1 billion in 2040 (€9.5 billion to €17.6 billion for diagnosed cases).
CONCLUSIONS: The projected increase in costs will be attributable to demographic changes and disease dynamics, and will be enhanced by higher per capita costs with advancing age. Better epidemiological and economic data regarding diabetes care in Germany would improve the forecasting accuracy. The method used in the present study can anticipate the effects of alternative policy scenarios and can easily be adapted to other chronic diseases.
© 2013 The Authors. Diabetic Medicine © 2013 Diabetes UK.

Entities:  

Mesh:

Year:  2013        PMID: 23506452     DOI: 10.1111/dme.12177

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  18 in total

1.  Dietary fiber intake and risk of type 2 diabetes: a dose-response analysis of prospective studies.

Authors:  Baodong Yao; Hong Fang; Wanghong Xu; Yujie Yan; Huilin Xu; Yinan Liu; Miao Mo; Hua Zhang; Yanping Zhao
Journal:  Eur J Epidemiol       Date:  2014-01-05       Impact factor: 8.082

2.  Years of life lost.

Authors:  Ralph Brinks; Annika Hoyer; Teresa Tamayo; Bernd Kowall; Wolfgang Rathmann
Journal:  Dtsch Arztebl Int       Date:  2015-03-20       Impact factor: 5.594

3.  How to defuse a demographic time bomb: the way forward?

Authors:  J C Buchan; W Amoaku; B Barnes; A Cassels-Brown; B Y Chang; J Harcourt; D Shickle; A F Spencer; S A Vernon; C MacEwen
Journal:  Eye (Lond)       Date:  2017-06-16       Impact factor: 3.775

4.  Prescription Patterns and the Cost of Antihyperglycemic Drugs in Patients With Type 2 Diabetes Mellitus in Germany.

Authors:  Louis Jacob; Christian von Vultee; Karel Kostev
Journal:  J Diabetes Sci Technol       Date:  2016-07-11

Review 5.  Economic Impact of Diabetes in Japan.

Authors:  Tatsuhiko Urakami; Remi Kuwabara; Kei Yoshida
Journal:  Curr Diab Rep       Date:  2019-01-16       Impact factor: 4.810

6.  Projection of osteoporosis-related fractures and costs in China: 2010-2050.

Authors:  L Si; T M Winzenberg; Q Jiang; M Chen; A J Palmer
Journal:  Osteoporos Int       Date:  2015-03-12       Impact factor: 4.507

7.  Change rates and prevalence of a dichotomous variable: simulations and applications.

Authors:  Ralph Brinks; Sandra Landwehr
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

8.  Projection of Diabetes Population Size and Associated Economic Burden through 2030 in Iran: Evidence from Micro-Simulation Markov Model and Bayesian Meta-Analysis.

Authors:  Mehdi Javanbakht; Atefeh Mashayekhi; Hamid R Baradaran; AliAkbar Haghdoost; Ashkan Afshin
Journal:  PLoS One       Date:  2015-07-22       Impact factor: 3.240

9.  Projected effect of increased active travel in German urban regions on the risk of type 2 diabetes.

Authors:  Ralph Brinks; Annika Hoyer; Oliver Kuss; Wolfgang Rathmann
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

10.  Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.

Authors:  Rüdiger Göke; Giovanni Bader; Markus Dworak
Journal:  Diabetes Ther       Date:  2014-03-19       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.